Across Australia, online wellness clinics have found a quiet passage through the architecture of medical regulation, selling unapproved peptide injections to thousands of people seeking to slow ageing and recover faster. The substances — with names like BPC-157 and CJC-1295 — have not been proven safe or effective in humans, yet they remain legal to sell because two separate regulatory bodies, the TGA and Ahpra, each assume the other holds the door. This is less a story of lawbreaking than of a system whose seams have been discovered and stretched — and of a government that has shown, at least
Australian wellness clinics exploit regulatory gaps to sell unapproved anti-ageing peptides
Consumers purchasing unapproved peptides risk unknown contents, incorrect dosing, sterility issues, and serious health harms including elevated cancer risk from growth factor elevation.
They are trying to look after their health, but relying on promises the evidence cannot support.
Mark
Why do these clinics exist at all? Surely the TGA could just shut them down?
Mimi
The TGA could, but it's caught between competing pressures. These peptides are unapproved, not banned. And the clinics exploit a real exemption—compounding for individual patients—that exists for legitimate reasons. The regulator has limited resources and has to choose where to focus.
Mark
So it's a resource problem?
Mimi
Partly. But it's also structural. The TGA oversees products; Ahpra oversees practitioners. When a clinic operates online and compounds peptides, it's not clear who should act first. By the time one regulator moves, the clinic has already shifted its operation.
Mark
What happens to someone who gets seriously hurt?
Mimi
That's the hard part. If the peptide causes harm, the person might sue the clinic or the doctor. But the clinic may have dissolved or moved offshore. And proving causation is difficult when the contents of the vial were never verified by anyone.
Mark
The 2019 Peptide Clinics case—why did that work?
Mimi
Because it was about advertising, not the product itself. Advertising prescription medicines to the public is clearly illegal. The court didn't have to prove anyone was harmed; it just had to show the business model depended on breaking that law. That's why advertising cases are the TGA's clearest wins.
Mark
Could the government just ban compounding for peptides, like it did for Ozempic?
Mimi
Yes. That's probably the most direct fix. It would close the loophole without requiring new laws. But it would also mean people with legitimate prescriptions couldn't get compounded versions if an approved alternative didn't exist.
The Pulse
- Online clinics are prescribing unapproved peptide injections after little more than a questionnaire, charging consumers over A$1,000 for substances that carry unknown contents, incorrect dosing risks, and a potential link to elevated cancer risk.
- A compounding exemption designed for individual patient care has been quietly repurposed as a bulk manufacturing operation, with clinics labelling mass-produced injection pens as personal prescriptions to sidestep TGA licensing requirements.
- The TGA and Ahpra each hold partial jurisdiction, creating a regulatory blind spot that enforcement warnings alone — including a fresh notice issued this week — have repeatedly failed to close.
- The most decisive action so far came not from patient harm but from advertising law, when a 2019 Federal Court ruling fined Peptide Clinics A$10 million and effectively collapsed the company — yet the broader trade continues.
- The government has a proven template: in 2024 it removed weight-loss drugs from the compounding exemption after widespread misuse, and experts say the same mechanism could be applied to peptides without any new legislation.
Across Australia, online wellness clinics have found a quiet passage through the architecture of medical regulation, selling unapproved peptide injections to thousands of people seeking to slow ageing and recover faster. The substances — with names like BPC-157 and CJC-1295 — have not been proven safe or effective in humans, yet they remain legal to sell because two separate regulatory bodies, the TGA and Ahpra, each assume the other holds the door. This is less a story of lawbreaking than of a system whose seams have been discovered and stretched — and of a government that has shown, at least once before, that it knows how to sew them shut.
Across Australia, a network of online clinics has built a lucrative business selling injections that promise to slow ageing, build muscle and improve sleep. A recent ABC 4 Corners investigation found doctors prescribing multiple peptides — so-called "stacks" — after nothing more than a questionnaire and a phone call. Substances like BPC-157, CJC-1295 and TB-500 carry no TGA approval and no human trial evidence supporting their claimed benefits. A few weeks' supply typically costs more than A$1,000.
The risks are not merely theoretical. The TGA has warned that consumers cannot verify what is in the vial, whether the dose is correct, or whether it is sterile. Even a pure product carries danger: a single dose of CJC-1295 can elevate the growth factor IGF-1 up to threefold for more than a week — and elevated IGF-1 is considered a probable cause of breast cancer.
The legal architecture enabling this trade rests on a gap between two regulators. The TGA licenses medicines and manufacturers; Ahpra oversees doctors and pharmacists. Between them lies a compounding exemption originally designed to let pharmacists prepare medicines for individual patients. Some clinics have stretched this rule to manufacture peptides in bulk, labelling each dose as a personal prescription to avoid TGA scrutiny. In substance, this is manufacturing. It requires a licence. It does not get one.
Enforcement has been fitful. The TGA typically begins with warnings and escalates slowly, constrained by resources and jurisdictional ambiguity. The clearest victory came through advertising law: in 2019, the Federal Court fined Peptide Clinics A$10 million for marketing prescription peptides directly to consumers, and the company collapsed. This week, the TGA issued another notice to suppliers, acknowledging that repeated warnings have not stopped the trade.
The people buying these injections are not reckless — they are seeking control over their health in a market that has outpaced regulation. But the government has demonstrated it can move quickly when it chooses. In 2024, it removed weight-loss drugs from the compounding exemption after online clinics had already supplied them to at least 20,000 Australians. The same mechanism could close the peptide loophole. No new laws are required — only the will to enforce and refine what already exists.
Across Australia, a sprawling network of online clinics has built a thriving business selling injections that promise to slow ageing, build muscle, mend injuries and improve sleep. Most operate entirely online. A recent ABC 4 Corners investigation documented a doctor prescribing multiple peptides—a so-called "stack"—after nothing more than a questionnaire and a phone call. The substances have names like BPC-157, CJC-1295 and TB-500. None of them are approved by Australia's Therapeutic Goods Administration. None have been demonstrated to work as advertised in human trials. And yet they remain legal to sell, because of a peculiar gap in how Australian medicine is regulated.
A peptide is simply a short chain of amino acids, the building blocks of protein. Some peptides, like insulin, are approved medicines that have passed rigorous safety and efficacy testing. The peptides sold by wellness clinics have not. The TGA, Australia's medicines regulator, has warned repeatedly that consumers cannot know what is actually in the vial, whether the dose is correct, or whether it is sterile. Even when pure, these substances carry real risks. A single dose of CJC-1295 can elevate a growth factor called IGF-1 up to threefold for more than a week. Elevated IGF-1 is considered a probable cause of breast cancer. A few weeks' supply of these injections typically costs more than A$1,000.
The regulatory architecture that allows this to happen is the product of two separate oversight bodies working at cross purposes. The TGA decides which medicines can be sold in Australia and licenses manufacturers. The Australian Health Practitioner Regulation Agency, or Ahpra, oversees doctors and pharmacists. The gap between them has become a highway. Clinics exploit a rule originally written to allow pharmacists to compound medicines for individual patients—say, making a liquid version of a tablet for someone who cannot swallow. But some clinics use this exception to manufacture peptides in bulk, labelling each dose "for a particular person" to avoid TGA scrutiny. Making the same recipe hundreds of times and posting it interstate as injection pens is, in substance, manufacturing. It requires a licence. It does not get one.
Some people import peptides for personal use with a valid prescription, which is lawful. Others obtain controlled imports that require an importation permit no patient can obtain. Importing without the right authority, or selling the substances on, is an offence. The law does not recognise a "research chemicals" exemption simply because a vial is labelled "not for human use." But the clinics themselves operate in a different legal space. The peptides are unapproved, yes—but they are not banned. The TGA regulates according to risk and resource. Even when a real danger is known, regulatory action may not follow if another agency has jurisdiction, or if enforcement is costly and unlikely to succeed.
The clearest enforcement victories have come not from patient harm but from advertising law. In 2019, the Federal Court fined Peptide Clinics A$10 million for advertising prescription peptides directly to the public, finding no genuine doctor-patient relationship behind the online sales. The company collapsed during the case. Advertising prescription medicines to the public carries penalties up to A$1.65 million per breach for an individual or A$16.5 million for a company. Yet the TGA rarely pursues cases to that extent. It typically begins with warnings and education, escalating only if those fail. This week, the TGA issued a fresh notice to suppliers and promoters, acknowledging that repeated warnings have not stopped the peptide trade.
The people buying these injections are not reckless. They are attempting to take control of their health and ageing. They may simply be relying on promises that clinical evidence does not support. The government has shown it can act decisively when it chooses. In 2024, it removed weight-loss drugs like Ozempic—which online clinics had already compounded and sold to at least 20,000 Australians—from the compounding exemption, along with gene therapies and medicinal cannabis. The same approach could apply to peptides. Alternatively, the TGA could be properly funded to pursue advertising breaches, or the compounding rule could be narrowed so it cannot function as a de facto bulk manufacturing licence. No new laws are necessary. The existing framework simply needs enforcement and refinement.
Notable Quotes
The TGA warns you often cannot be sure what is in the vial, whether the dose is right, or whether it is sterile.— Therapeutic Goods Administration
Repeated warnings have not stopped the peptide trade.— TGA, in recent notice to suppliers and promoters
Want the full story?
Read the original at The Conversation ↗
Health & Medicine